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ABSTRACT
Background Voltage-gated potassium channel
(VGKC)-complex antibodies can be associated with a
range of immunotherapy-responsive clinical presentations
including limbic encephalitis, Morvan’s syndrome and
acquired neuromyotonia. However, there are patients with
positive levels in whom the signiﬁcance is uncertain.
Objective To evaluate the clinical signiﬁcance
associated with positive (>100 pM) VGKC-complex
antibodies.
Methods Over a 4-year period, 1053 samples were
sent for testing of which 55 were positive. The clinical
presentations, ﬁnal diagnoses and responses to
immunotherapies, when given, were assessed
retrospectively and the likelihood of autoimmunity was
categorised as deﬁnite, possible, unlikely or
undetermined (modiﬁed from Zuliani et al 2012).
Results Only 4 of the 32 patients with low-positive
(100–400 pM) levels were considered deﬁnitely
autoimmune, 3 with peripheral nerve hyperexcitability
and 1 with a thymoma; 3 were given immunotherapies.
Of the remaining 28 with low-positive levels, 13 (3 of
whom had tumours) were considered possibly
autoimmune, and 15 were unlikely or undetermined;
1 was given immunotherapy unsuccessfully. Of the
23 patients with high-positive (>400 pM) levels, 12
were given immunotherapies, 11 of whom showed a
good response. 11 were considered deﬁnitely
autoimmune, 10 with limbic encephalitis (antibody
speciﬁcity: 5 LGI1, 1 contactin2, 2 negative, 2 untested)
and 1 with a tumour. In the remaining 12,
autoimmunity was considered possible (n=9; most had
not received immunotherapies), or unlikely (n=3).
Conclusions As antibody testing becomes more widely
available, and many samples are referred from patients
with less clear-cut diagnoses, it is important to assess
the utility of the results. VGKC-complex antibodies in the
range of 100–400 pM (0.1–0.4 nM) were considered
clinically relevant in rare conditions with peripheral nerve
hyperexcitability and appeared to associate with tumours
(12.5%). By contrast high-positive (>400 pM; >0.4 nM)
levels were considered deﬁnitely (38%) or possibly
(49%) clinically relevant, but not all patients had a
‘classical’ limbic encephalitis and some did not receive
immunotherapies.
INTRODUCTION
Autoantibodies against the voltage-gated potassium
channel (VGKC) complex measured by radioimmu-
noprecipitation have been reported in a broad
spectrum of immunotherapy-responsive neurological
illnesses in children and adults. Initially, low levels
(<400 pM) were associated with peripheral nerve
hyperexcitability syndromes (mainly acquired neuro-
myotonia), but higher levels were subsequently found
in Morvan’s syndrome, and in patients with reversible
limbic encephalitis.1–4 In the ﬁrst case series, 10
patients with limbic encephalitis had VGKC-complex
values from 450 to 5128 pM, but some controls were
reported to have low positive titres.5 Many subse-
quent reports have conﬁrmed that VGKC-complex
antibodies are associated with limbic encephalitis and
a broader range of phenotypes, and in some patients,
VGKC-complex antibodies <400 pM did appear to
be clinically relevant.6
Latterly it has become clear that VGKC anti-
bodies are not directed against the VGKC itself, but
against other cell surface antigens that form part of
the VGKC complex. Antigenic targets include
leucine-rich glioma-inactivated protein 1 (LGI1),7
typically associated with limbic encephalitis (LE)
and a distinctive seizure disorder, faciobrachial dys-
tonic seizures8 and contactin-associated protein 2
(CAPSR-2), more frequently associated with per-
ipheral nerve hyperexcitability syndromes including
Morvan’s syndrome (neuromyotonia, neuropsychi-
atric features, sleep disturbance, dysautonomia).9
Antibodies to Contactin2 are much less frequent
with no syndrome-speciﬁc phenotype having been
identiﬁed. However, in a proportion of patients
with positive VGKC-complex antibodies, a speciﬁc
antigenic target has not been deﬁned, suggesting
that the antibodies may be directed against other
antigens within the complex and raising questions
about the antibody speciﬁcity and relevance.
To investigate the relevance of VGKC-complex
antibodies in routine clinical practice, we per-
formed a retrospective analysis of a large case series
of individuals from one institution where antibody
testing had been requested as part of the diagnostic
work-up. We speciﬁcally aimed to address the rele-
vance of low-positive versus high-positive antibody
levels, and whether discovery of a positive antibody
inﬂuenced management.
METHODS
Following an initial brief audit of 44
VGKC-complex antibody-positive subjects, we per-
formed a comprehensive retrospective review of all
patients seen at the National Hospital for
Neurology and Neurosurgery, Queen Square, who
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had VGKC antibodies requested between January 2008 and
January 2012. The electronic records of clinic correspondence,
neuropsychology, imaging and other blood results were
reviewed. Subjects were classiﬁed as having ‘high positive’
(≥400 pM) or ‘low positive’ (100 to 400 pM) VGKC-complex
antibodies. Duration of follow-up was deﬁned as the time from
the ﬁrst to the most recent neurological assessment. The treating
neurologist’s ﬁnal diagnosis was recorded. The likelihood of
each patient having an autoimmune VGKC-complex
antibody-related syndrome was retrospectively determined using
a modiﬁed version of previously published guidelines10 11
(tables 1 and 2).
SEROLOGY
Serum VGKC-complex antibodies were tested using a radioim-
munprecipitation assay.3 Cell-based assays for CASPR2, LGI1
and contactin 2 antibodies were performed using human embry-
onic kidney cells transfected with cDNAs encoding the relevant
proteins.9
RESULTS
An initial audit of 44 VGKC-complex antibody-positive patients
demonstrated that 32 had values <400 pM, of whom 90% were
not considered to be autoimmune, whereas 9 of the 12 with higher
levels were considered to have an immunotherapy-responsive auto-
immune disease. To study this more formally we collected all
results from 2008 to January 2012 inclusive.
During this time, the serum of 1053 subjects was tested for
VGKC-complex antibodies of whom 55 subjects (5.5%) had one
or more positive levels (>100 pM). Thirty-two subjects were
only ever low positive; and the remaining 23 had high-positive
levels at presentation or on subsequent sampling. A summary of
clinical presentation, VGKC-complex, LGI1 and CASPR2 anti-
bodies and treatment responses (where available) in the low- and
high-positive groups are given in tables 1 and 2, ordered accord-
ing to the likelihood of an autoimmune condition.
Low-positive patients
Thirty-two subjects, assessed in general neurology, specialist cog-
nitive disorders, neuromuscular and movement disorder services,
only ever had low positive levels (100–400 pM; mean age 52 (SD
18.8), male:female ratio 0.9:1). Many of these subjects had
symptoms for many months (median 24, range 1–132 months) at
the time the antibodies were ﬁrst measured. They were followed
up for a median of 23.5 (0–48) months. Four had more than one
VGKC-complex antibody measured, and in three the subsequent
samples were within the normal range (<100 pM).
Only four of these patients (13%) were considered to have a
deﬁnite or probable autoimmune disease (one with a paraneo-
plastic cerebellar syndrome, one with acquired neuromyotonia
and two with Morvan’s syndrome). The latter two patients were
given immunotherapies, although only one (a patient with
Morvan’s and a prior thymoma resection) showed a signiﬁcant
improvement (reduction in modiﬁed Rankin score from 5 to 3).
The remaining 28 patients had a variety of peripheral (n=3),
central (n=17) or psychiatric (n=4) disorders; no deﬁnite diag-
nosis was made in four patients (see table 1). Although 13 indi-
viduals were retrospectively categorised on the basis of clinical
features and investigations as possibly having an autoimmune
disorder, none was given immunotherapy. Antibodies directed
against LGI1 or CASPR2 antibodies were present in only 3 of
the 32 patients (table 1). Two of these had peripheral nerve
hyperexcitability, but they were not given immunotherapy.
Three of the 32 patients had a malignancy ﬁrst detected
around the time the antibodies were tested (endometrial cancer
in one, breast cancer in two); a further three subjects were
screened for malignancy with whole body ﬂuorodeoxyglucose
(FDG) PET scanning which was negative in each case.
High-positive patients
Seventeen patients had high levels of VGKC-complex antibodies
(>400 pM) ranging from 401 to 6846 pM when ﬁrst tested,
and a further six individuals initially had low values which rose
to high on subsequent sampling. The clinical features are sum-
marised in table 2.
The mean age was 59 (SD 19.4) with a male:female ratio of
1.3:1, and median time from symptom onset to VGKC-complex
measurement of 30 months (range 0.5–206). On the basis of the
clinical syndrome and/or response to immunotherapies, 11
(including one individual fulﬁlling criteria for paraneoplastic
disease) were retrospectively classiﬁed as having a deﬁnite auto-
immune condition. Ten individuals had limbic encephalitis, of
whom six of eight tested had LGI1 (5) or contactin-2 (1) anti-
bodies. These 10 patients were treated with immunotherapies
and showed a good response to treatment. Nine of the remain-
der were retrospectively assessed as possibly having an auto-
immune condition but were not given immunotherapies. Two
other individuals had a neurodegenerative condition, and one
had hepatic toxicity.
Overall, the suggested autoimmune categories (ﬁgure 1) were
related to the antibody titre (ﬁgure 2A; p=0.013, Fisher’s exact
test). It was noted that the median time from symptom onset to
antibody testing was six months (range 0.5–120) in those patients
considered to have a deﬁnite VGKC-complex-related disease
compared with 28 months (range 0.5–206) in those classiﬁed as
possible or unlikely (ﬁgure 2B; p=0.04, Kruskal–Wallis test).
DISCUSSION
In this unselected retrospective series of adults seen in a tertiary
neurology setting, 5.5% of patients showed a positive
VGKC-complex antibody result. While the range of conditions
in which antibody testing was requested, was inevitably subject
to referral bias and may not be entirely representative of the
patients seen in a less specialised setting, when we considered
retrospectively the likelihood of an autoimmune basis for the
disorders,10 high positive values were more common in condi-
tions well described in the context of VGKC-complex anti-
bodies, such as limbic encephalitis, whereas low positive values
were more likely to have an alternative, non-autoimmune or
unclear diagnosis. The results conﬁrm that high titres of VGKC
antibodies are very likely to be clinically relevant, particularly
when tested within a few months of onset, whereas values
<400 pM should be interpreted with care. Nevertheless, the
relatively high number (4/32, 13%) of low-positive cases with
tumours suggests that low-positive VGKC-complex antibody
levels may be an onconeural marker in some situations.11–13
Many of the ‘high-positive’ patients had limbic encephalitis or
related syndromes (relapsing encephalopathy, seizures), although
one subject had an alternative autoantibody (anti-glutamate
decarboxylase (GAD)) that was consistent with their neuro-
logical presentation of Stiff Person Syndrome. Although the
patients with limbic encephalitis were treated with good
responses, neurologists had exercised their clinical judgement in
not trying immunotherapy for most of the related syndromes,
which, therefore, were deﬁned as ‘possible’ autoimmune. By
contrast, the ‘low-positive’ patients had many more neurodegen-
erative diagnoses, atypical presentations or uncertain diagnoses,
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and only 12% were considered to have a deﬁnite autoimmune
condition, and only four were given immunotherapy.
Importantly, no patient with a VGKC-complex level <400 pM
had limbic encephalitis or epilepsy of unknown aetiology,
although such patients have been identiﬁed elsewhere,6 and low-
positive VGKC levels have been associated with classical auto-
immune syndromes in a few children.14 15
As so many of the low-positive cohorts had unrelated or alter-
native diagnoses, these data provide strong evidence that consid-
erably less weight should be put on a low- rather than a
Table 1 Clinical features in patients with VGKC-complex antibodies <400 pM
Subject
Highest VGKC levels;
other specific antibody if
found*
Physician’s diagnosis/duration of
follow-up CSF (cerebrospinal fluid)
Response to
immunotherapies
VGKC-complex
related syndrome
M, 57 398 Morvan’s syndrome/34 months 2 WC; Pro N Yes Definite
M, 72 168 Morvan’s syndrome and CIDP/
36 months; Thymoma
NT Yes Definite
F, 71 124, NT Autoimmune/paraneoplastic cerebellar
syndrome; Endometrial carcinoma
1 WC, Pro 0.64, cytology, culture
negative
No Paraneoplastic
F, 67 301/LGI1 Neuromyotonia/9 months NT Not tried Definite
F, 69 144, NMDAR low, GlyR Amnesia/23 months Acellular, Pro N, cytology −ve Not tried Possible
F, 64 170 None made/28 months Acellular, Pro 0.7, OCB +ve serum
and CSF
Not tried Possible
M, 25 173 Brainstem migraine/6 months <1 WC, 16 RC, Pro 0.43, Culture
−ve
Not tried Possible
F, 22 316 Idiopathic generalised epilepsy/
9 months
46 WC, (lymph); 4 RC, Pro 0.46,
Culture −ve; OCB +ve CSF only
Not tried Possible
M, 86 358/LGI1 and CASPR2 Idiopathic Parkinson’s disease/
3 months
NT Not tried Possible
F 40 391 Myoclonic jerks of undetermined
aetiology/7 months
NT Not tried Possible
M 48 201 Infective encephalopathy
improvement with antibiotics/
24 months
7 WC (lymph); 0 RC, Pro N,
Culture −ve
Not tried Possible
M, 18 117/LGI1 and CASPR2 Nerve hyperexcitability syndrome/
18 months
NT Not tried Possible
M, 55 100 Length dependent sensory axonal
neuropathy/13 months
NT Not tried Possible
F, 38 149 Suspected muscle channel disease/
44 months
NT Not tried Possible
F, 43 212 Dystonia of undetermined aetiology/
40 months, Breast cancer
WC<1, RC 1200, OCB +ve in CSF
and serum, Pro 0.7
Not tried Possible paraneoplastic
F, 42 138 Functional movement disorder/
51 months, Breast cancer
Acellular, Pro N, OCB −ve Not tried Possible Paraneoplastic
F, 23 186 None made, spontaneous
improvement/6 months
Acellular; Pro N; OCB −ve Not tried Possible
M, 64 143 Multi-system atrophy/60 months <1WC, 8 RC, OCB −ve, cytology
−ve
IVIG, no improvement Unlikely
F, 61 183 Alzheimer’s disease/34 months NT Not tried Unlikely
F, 75 221 Lewy Body Dementia/8 months Acellular, Pro N Not tried Unlikely
M, 75 130 Embolic stroke secondary to atrial
fibrillation/6 months
32 RC, <1 WC, Pro N Not tried Unlikely
M, 74 106 Alzheimer’s disease/12 months Acellular, Pro N Not tried Unlikely
M, 54 118 Motor Neurone disease/24 months NT Not tried Unlikely
F, 57 119 Lewy Body dementia/vascular
dementia/24 months
NT Not tried Unlikely
M, 70 162 Depression/12 months NT Not tried Unlikely
F, 18 352 Allgrove syndrome/7 months Acellular; Pro N Not tried Unlikely
M, 62 126 Alcohol withdrawal NT Not tried Unlikely
F, 60 108 Anxiety disorder NT Not tried Undetermined
M, 37 118 Psychological disorder NT Not tried Undetermined
F, 34 119 None made NT Not tried Undetermined
F, 62 124 None made NT Not tried Undetermined
M, 38 103 None made NT Not tried Undetermined
*All available samples were tested for LGI1 and CASPR2; most were not tested for contactin-2. Likelihood of VGKC-complex antibody being related to autoimmunity was determined
based on previously published guidelines10 11 modified as follows: definite: recognised neurological syndrome and treatment with immunotherapy successful; possible: recognised or
possible neurological syndrome and immunotherapy unsuccessful or untried; unlikely: unrelated clinical syndrome and more likely alternative diagnosis; undetermined: unrelated clinical
syndrome and no likely relevance. Some samples were not available for retesting (NA).
CIDP, chronic idiopathic demyelinating polyneuropathy; LGI1, leucine-rich glioma-inactivated 1; NMDAR, methyl-D-aspartate; N, normal; NT, not tested; OCB, oligoclonal bands; Lymph,
lymphocytes; Pro, protein (normal range < 0.65 g/l); RC, red cells; VGKC, voltage-gated potassium channel; WC, white cells.
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high-positive antibody level. An exception to this is in the
context of peripheral nerve hyperexcitability consistent with
neuromyotonia, where VGKC-complex antibodies at low levels
are common1 and do not necessarily show binding to LGI1 or
CASPR2 (Vincent, M Kiernan, O Watanabe, unpublished data).
Thus, we suggest that low-positive VGKC-complex antibodies
may be secondary to other disease pathologies, and it is possible
that they are part of a normal repertoire of autoantibodies found
in otherwise healthy individuals, which can, under certain cir-
cumstances, rise to detectable levels. It is notable that a signiﬁcant
proportion of the low-positive cohorts was diagnosed with a neu-
rodegenerative disorder and in one case with a genetically
deﬁned disease, Allgrove syndrome.16 In keeping with recent
reports that VGKC levels can occasionally be elevated in cases of
Creutzfeld Jacob disease,17 these cases demonstrate that elevated
antibodies can be found in degenerative neurological diseases,
when their presence is unlikely to be clinically relevant.
The number of subjects (3/32, 9.4%) who were positive for
LGI1 or CAPSR2 in the low-positive VGKC cohort was signiﬁ-
cantly lower than that (6/20, 30%) of the unselected high-
positive subjects (χ2 4.5, p=0.034) and that (6/8, 75%) of the
limbic encephalitis subjects tested. However, two patients with a
deﬁnite clinical diagnosis of autoimmune limbic encephalitis
were not positive for LGI1 or CASPR2 antibodies, suggesting
that there are other antibody targets within the VGKC complex
as suggested previously9 and by others.18 Those with high-
positive VGKC-complex and LGI1 antibodies all had limbic
encephalitis, conﬁrming that LGI1 antibodies are common in
this condition.7
A relatively high proportion (three cases, 10%) of patients
with low-positive antibodies had tumours (three with breast
cancer, one with endometrial carcinoma) and one further subject
had a thymoma that was resected before he presented. This is sig-
niﬁcantly higher than the expected incidence within the general
Table 2 Clinical features in patients with VGKC-complex antibodies >400 pM
Subject
Highest VGKC levels/
specific antibody if
found* Physician’s diagnosis/duration of follow-up CSF
Response to
immunotherapies
Autoimmune
likelihood
M, 61 453, LGI1 Limbic encephalitis/60 months NA Yes Definite
F, 62 751, LGI1 Limbic encephalitis Acellular; Pro N; OCB
−ve
Yes Definite
M, 54 1032, LGI1 Limbic encephalitis/24 months Acellular, Pro N Yes Definite
F, 83 1555, LGI1 Limbic encephalitis/31 months NT Yes Definite
M, 70 6846, LGI1 Limbic encephalitis/20 months NA Yes Definite
M, 74 1098, Contactin2 Possible limbic encephalitis/36 months 5 WC (lymph); Pro 0.55
matched OCB
Yes Definite
M, 68 5067 Limbic encephalitis/38 months Acellular; Pro N; matched
OCB
Yes Definite
M 56 555 Limbic encephalitis/63 months WC<1, RC 8, Pro N,
matched OCB
Yes Definite
F, 74 2208, NT Limbic encephalitis/52 months NT Yes Definite
M, 73 555, NT Limbic encephalitis/6 months Acellular; Pro 0.83, OCB
−ve
Yes Definite
M, 72 857 Paraneoplastic syndrome; bladder cancer Acellular; Pro 1.59; OCB
−ve
Not tried Paraneoplastic
F, 52 454 Neuromyotonia associated with VGKC antibodies/
38 months
NT Not tried Possible
M, 40 552 Stiff person syndrome/30 months, GAD Ab positive 1 WC; 2 RC, Pro N Yes, partial Possible
F, 44 1652 Cognitive and cerebellar syndrome/50 months WC 3; RC 1200; Pro N;
OCB +ve CSF and serum
Equivocal Possible
F, 67 548 Choreiform movement disorder of undetermined
aetiology/39 months
WC<1; RC 72; Pro 0.49 Not tried Possible
M, 38 569 Possible mitochondrial disease, possible acquired
neuromyotonia, possible periodic paralysis/
36 months
NT Not tried Possible
F, 25 1084 Intractable childhood onset focal epilepsy of
undetermined aetiology/13 months
NT Not tried Possible
M, 22 1477 Asperger’s syndrome + elevated VGKC of
undetermined aetiology/60 months
Acellular; Pro N, OCB
−ve.
Not tried Possible
M, 30 4893 Intractable epilepsy aetiology undetermined/
6 months
NT Not tried Possible
M, 60 448 Possible periodic paralysis NT Not tried Possible
M, 58 987, NT Hepatic encephalopathy (evidence of liver failure
and raised ammonia)/1 month
NT Not tried Unlikely
M, 69 868 Frontotemporal lobar degeneration/20 months Acellular; Pro N; OCB
−ve
Not tried Unlikely
F, 80 969 Lewy body dementia/7 months Acellular, Pro N, OCB +ve
CSF and serum
Not tried Unlikely
See footnote to table 1.
*120; low-grade peripheral nervous system symptoms for 120 months, with new symptoms developing 6 months before the diagnosis of cancer.
GAD, glutamate decarboxylase; NT, not tested; OCB, oligoclonal bands; RC, red cells; VGKC, voltage-gated potassium channel; WC, white cells.
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population (0.004% per annum age in the 40–59 age range;
0.014% per annum in the 60–74 age range, http://www.cancerre-
searchuk.org/cancer-info/cancerstats) and very similar to another
recent study.18 While the long duration of neurological symp-
toms without overt evidence of malignancy in a signiﬁcant pro-
portion of cases is reassuring, and screening for malignancy may
well have been prompted by other factors, the prevalence of
underlying malignancy in the low-positive group as a whole is
unknown and should be the focus of further study.13
Recently, Klein et al18 reported the clinical presentations of a
larger group of VGKC-complex positive patients showing that a
small proportion of low-positive VGKC-complex patients are
also positive for LGI1 or CASPR2. Although clinical follow-up
of these cases was limited, they suggest that these are more likely
to be of clinical relevance. Our ﬁndings are broadly compatible
with their ﬁndings; patients with lower antibody titres were less
likely to have a speciﬁc antigenic target or to have a probable
autoimmune condition, except those with LGI1 or CASPR2 anti-
bodies and/or with hyperexcitability syndromes. However, one
patient with idiopathic Parkinson’s disease and VGKC antibodies
at 358 pM was positive for LGI1 and CASPR2 antibodies but
was not considered by the treating neurologist to have a deﬁnite
autoimmune diagnosis and was not treated as such.
It is not clear why high antibody titres are more associated
with central nervous system disorders, often without peripheral
dysfunction, while low antibody titres cluster more with periph-
eral hyperexcitability. Certainly very high VGKC/LGI1 anti-
bodies are associated with limbic encephalitis,7 9 as shown here,
but lower levels of both can be found in peripheral nerve hyper-
excitability. Such examples serve to illustrate that antibody
results need always to be interpreted in the clinical context, and
that our understanding of the pathophysiological underpinnings
of many of these syndromes is still incomplete. Nevertheless,
the broad rule of thumb that low-positive titres—particularly
without a speciﬁc antigenic target—are less likely to be relevant
is of potential clinical utility.
In conclusion, in this retrospective series, high-positive VGKC
antibodies strongly predicted an autoimmune or possibly auto-
immune aetiology, suggesting that the cut-off that we use for a
high-positive antibody level (>400 pM) has clinical utility, at
least for adults. By contrast, the majority of patients with low-
positive VGKC-complex antibodies did not have an identiﬁable
antigenic target, or a syndrome thought to be related to the
presence of the antibodies; in many patients, a deﬁnite alterna-
tive diagnosis was reached, and the result rarely altered manage-
ment. In some cases, however, low-positive VGKC-complex
antibodies may reﬂect a broader autoimmune tendency. The
possibility of an occult—perhaps unrelated—neoplasm should
always be considered in individuals with a deﬁnite or possible auto-
immune syndrome. While our data suggest a possible increased risk
of an occult tumour in individuals with isolated low-positive anti-
bodies, irrespective of the clinical syndrome, in most patients, these
antibodies are not markers of paraneoplasia and further studies are
required to demonstrate whether and which occult tumours should
be actively sought. These data suggest that, particularly in the
absence of a speciﬁc antigenic target or a phenotype associated
with VGKC-complex antibodies (eg, limbic encephalitis, faciobra-
chial dystonic seizures, neuromyotonia), low positive antibodies
should be interpreted with care. In case of doubt antibody levels
should be rechecked after an interval to ensure they are not rising.
Figure 2 (A) The number of patients in each of the given categories
divided between high and low voltage-gated potassium
channel-complex antibodies (p=0.004, χ2, analysed on GraphPad
Prism). (B) The duration of symptoms at sampling in patients divided
between deﬁnite, possible and unlikely or undetermined categories.
One-way ANOVA, p=0.04.
Figure 1 Summary of all patients tested for voltage-gated potassium
channel antibodies, their diagnostic classiﬁcation and autoimmune
probability.
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